Market closedNon-fractional
Amicus Therapeutics/FOLD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Amicus Therapeutics
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Ticker
FOLD
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Princeton, United States
Employees
517
Website
amicusrx.com
FOLD Metrics
BasicAdvanced
$3B
Market cap
-
P/E ratio
-$0.49
EPS
0.79
Beta
-
Dividend rate
Price and volume
Market cap
$3B
Beta
0.79
Financial strength
Current ratio
3.035
Quick ratio
2.224
Long term debt to equity
333.774
Total debt to equity
340.101
Interest coverage (TTM)
-1.14%
Management effectiveness
Return on assets (TTM)
-5.08%
Return on equity (TTM)
-126.10%
Valuation
Price to revenue (TTM)
7.221
Price to book
23.27
Price to tangible book (TTM)
-35.04
Price to free cash flow (TTM)
-34.74
Growth
Revenue change (TTM)
25.74%
Earnings per share change (TTM)
-30.15%
3-year revenue growth (CAGR)
16.66%
3-year earnings per share growth (CAGR)
-20.24%
What the Analysts think about FOLD
Analyst Ratings
Majority rating from 12 analysts.
FOLD Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$110M
-4.00%
Net income
-$48M
43.20%
Profit margin
-43.84%
49.17%
FOLD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.15
-$0.07
-$0.11
-$0.16
-
Expected
-$0.12
-$0.08
-$0.06
-$0.07
-$0.05
Surprise
21.62%
-7.35%
86.79%
144.07%
-
FOLD News
AllArticlesVideos
In NCLA Amicus Win, Fifth Circuit Rules Against FCC's Unlawful Control of Universal Service Fund
GlobeNewsWire·2 days ago
In NCLA Amicus Win, Supreme Court Upholds Small Business's Right to Judicial Review
GlobeNewsWire·4 weeks ago
In NCLA Amicus Win, Supreme Court Restores Americans' Rights to Trial by Jury
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amicus Therapeutics stock?
Amicus Therapeutics (FOLD) has a market cap of $3B as of July 27, 2024.
What is the P/E ratio for Amicus Therapeutics stock?
The price to earnings (P/E) ratio for Amicus Therapeutics (FOLD) stock is 0 as of July 27, 2024.
Does Amicus Therapeutics stock pay dividends?
No, Amicus Therapeutics (FOLD) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Amicus Therapeutics dividend payment date?
Amicus Therapeutics (FOLD) stock does not pay dividends to its shareholders.
What is the beta indicator for Amicus Therapeutics?
Amicus Therapeutics (FOLD) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Amicus Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.